Latest Hotspot

Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial

15 September 2023
3 min read

Updated results from a subgroup analysis of a phase 1/2 trial showed that ifinatamab deruxtecan (I-DXd) continues to demonstrate durable responses in patients with heavily pretreated advanced small cell lung cancer. These data were presented today during an oral presentation at the 2023 World Conference on Lung Cancer.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Ifinatamab deruxtecan is a specifically engineered potential first-in-class B7-H3 directed antibody drug conjugate designed using Daiichi Sankyo’s proprietary DXd ADC technology.

Lung cancer is the second most common cancer worldwide and SCLC represents about 15% of all cases. Approximately 65% of all SCLC tumors have a moderate-to-high expression of B7-H3, which is associated with disease progression and lower survival.

Tumor reduction seen with ifinatamab deruxtecan was observed across a broad range of B7-H3 protein expression levels and no apparent trend of correlation between clinical efficacy parameters and B7-H3 protein expression was observed.

“With limited effective treatment options beyond traditional chemotherapy and immunotherapy, small cell lung cancer can be difficult to treat,” said Melissa Johnson, MD, Director, Lung Cancer Research, Sarah Cannon Research Institute. “The high response rate, along with the fact that all patients except one experienced a reduction in tumor size with ifinatamab deruxtecan, is promising.”

“In addition to the response rate seen with ifinatamab deruxtecan, we are further encouraged by the median overall survival seen in these patients at approximately one year,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo. “Additional evaluation of this B7-H3 directed antibody drug conjugate is underway in our ongoing phase 2 trial in patients with previously treated extensive-stage small cell lung cancer and we look forward to learning these results.”

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of September 14, 2023, there are 2 investigational drugs for the CD276 and TOP1 target, including 7 applicable indications,5 R&D institutions involved, with related clinical trials reaching 6and as many as 91 patents.

Ifinatamab deruxtecan (I-DXd) is an investigational potential first-in-class B7-H3 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology. Ifinatamab deruxtecan is being evaluated in a global development program, a phase 2 monotherapy trial in patients with previously treated extensive-stage SCLC, and a phase 1/2 first-in-human trial in collaboration with Sarah Cannon Research Institute.

图形用户界面, 文本, 应用程序

描述已自动生成

Advancements in Clinical Research on CDK5 Inhibitors
Advancements in Clinical Research on CDK5 Inhibitors
15 September 2023
CDK5, or cyclin-dependent kinase 5, is a crucial enzyme found in the human body that plays a significant role in various physiological processes.
Read →
Bristol Myers Squibb's trial LPA1 Antagonist reduced lung function decline in Progressive Pulmonary Fibrosis patients in a phase 2 study
Latest Hotspot
3 min read
Bristol Myers Squibb's trial LPA1 Antagonist reduced lung function decline in Progressive Pulmonary Fibrosis patients in a phase 2 study
15 September 2023
Bristol Myers Squibb's experimental LPA1 Antagonist showed promising results in reducing the rate of lung function decline in the Progressive Pulmonary Fibrosis group in a phase 2 clinical trial.
Read →
CDK4 Inhibitor - A Highly Noticed Breast Cancer Treatment Drug
CDK4 Inhibitor - A Highly Noticed Breast Cancer Treatment Drug
15 September 2023
CDK4, or cyclin-dependent kinase 4, is a crucial protein involved in cell cycle regulation in the human body.
Read →
Promising results were noted in Phase 1b of the TROPION-Lung04 trial, combining Datopotamab Deruxtecan and Durvalumab for Non-Small Cell Lung Cancer
Latest Hotspot
3 min read
Promising results were noted in Phase 1b of the TROPION-Lung04 trial, combining Datopotamab Deruxtecan and Durvalumab for Non-Small Cell Lung Cancer
15 September 2023
Promising clinical responses were observed in TROPION-Lung04's Phase 1b Trial with a combination of Datopotamab Deruxtecan and Durvalumab with Non-Small Cell Lung Cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.